By Fineline Cube 
China’s Peijia Medical Ltd (HKG: 9996) has announced the successful treatment of the first patient in the first-in-human (FIH) trial for its innovative ReachTactile robot-assisted transcatheter aortic valve replacement (TAVR) system. The procedure, performed by Professor Wang Yan and his team at Xiamen Cardiovascular Hospital, Xiamen University, utilized the ReachTactile system to implant a Taurus Elite transcatheter aortic valve in a patient with severe aortic stenosis.
Innovative Technology
ReachTactile is an internally developed robot-assisted TAVR system designed with a modular and mobile architecture. This advanced system allows cardiologists to operate multiple instruments with sub-millimeter precision, making it suitable for traditional vascular intervention catheterization rooms. Its precision and flexibility highlight Peijia Medical’s commitment to advancing minimally invasive cardiac interventions.
Clinical Trial Progress
The initiation of the FIH trial marks a significant milestone in the development of ReachTactile. The trial aims to evaluate the safety and efficacy of the system in patients with severe aortic stenosis, a condition that affects a significant population and requires precise and effective treatment solutions.-Fineline Info & Tech